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Abstract
Background: Asthma patients are enrolled in multimodal pulmonary rehabilitation (PR) programs. However,
available data for the effectiveness of PR in asthma are sparse. Therefore, the primary aim of this randomized
control trial (RCT) is to evaluate short-term (end of rehabilitation) and intermediate-term effectiveness (3 months
after rehabilitation) of PR for patients with asthma regarding asthma control (primary outcome) and other
outcomes. Secondly, moderator effects of gender, age, baseline asthma control, quality of life, and anxiety will be
examined. Thirdly, a longitudinal follow-up study will explore the course of the outcomes over one year and the
annual costs.
Methods: The EPRA study is a single-center randomized controlled waiting-list trial in the Bad Reichenhall Clinic.
Inclusion criteria include a referral diagnosis for uncontrolled asthma, no cognitive impairment and no very severe
co-morbidities that indicate significantly greater illness morbidity than asthma alone. In the intervention group (IG),
participants will start PR within 4 weeks after randomization; participants of the control group (CG) will start PR 20
weeks after randomization. Data will be assessed at randomization (T0), after 4 weeks (T1; IG: begin of PR), 7 weeks
(T2; IG: end of PR), and 20 weeks (T3, CG: begin of PR). The primary outcome is asthma control at T2/T3. Secondary
outcomes are health-related quality of life, functional exercise capacity, dyspnea, anxiety, depression, subjective self-
management skills, illness perceptions, sick leave and subjective work ability. Outcomes will be analyzed with
analysis of covariance, including baseline values of the respective outcomes as covariates. Healthcare costs will be
analyzed with a gamma model with a log-link.
A longitudinal follow-up study will generate additional data at 3/6/9/12 months after PR for both IG and CG. Latent
change models will be used to analyze the course of the primary and secondary outcomes. Annual cost differences
before and after rehabilitation will be compared by paired t-test.
Discussion: This RCT will determine the effectiveness of a complex inpatient PR for asthma patients concerning
asthma control. Furthermore, important medical and economic information regarding the effectiveness of PR as
part of the long-term management of patients with uncontrolled asthma will be generated.
Trial registration: German Clinical Trials Register (DRKS00007740, May 15, 2015). Protocol version: 1.0 (December,
23, 2016).
Keywords: Pulmonary rehabilitation, Asthma, RCT, Longitudinal study, Asthma control, ACT, Inpatient rehabilitation,
Randomized controlled trial, Longitudinal, Economic evaluation
* Correspondence: konrad.schultz@klinik-bad-reichenhall.de
1Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology and
Orthopedics, Bad Reichenhall, Germany
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




Asthma is one of the most common chronic diseases
worldwide with an estimated 300 million affected indi-
viduals [1]. Asthma was defined by the Global Initiative
for Asthma (GINA) as a heterogeneous disease, usually
characterized by chronic airway inflammation and a
history of respiratory symptoms that vary over time and
in intensity, including wheeze, shortness of breath, chest
tightness and cough, together with variable expiratory
airflow limitation [1]. Thus, the diagnosis of asthma is
primarily based on clinical symptoms [2]. In spite of the
availability of effective medications, it remains incurable.
Various cross-sectional studies have shown a high num-
ber of patients with poorly controlled asthma in many
countries [3, 4]. Therefore, new approaches to improve
asthma control (AC) are urgently required.
Pulmonary rehabilitation (PR) is widely accepted as an
effective treatment for patients with chronic respiratory
diseases, especially for chronic obstructive pulmonary
disease (COPD) [5]. In Europe and North America,
asthma patients are also commonly enrolled in PR
programs [6], but the available data regarding the effect-
iveness of PR for asthma patients are sparse. Only very
few randomized studies [7, 8] concerning the effective-
ness of a multimodal PR program in asthma have been
published. All had certain methodological limitations, so
that they weren’t considered for international evidence-
based asthma guidelines [1, 2].
However, the effectiveness of the essential individual
components of PR, such as patient education [9, 10],
respiratory physiotherapy [11, 12] and aerobic exercise
training [13–18] has been shown in several randomized
controlled trails (RCTs). As a complete PR program is
expected to be at least as effective as these single com-
ponents, the German National Disease Management
Guideline [19] recommends PR for asthma patients if
physical, mental or social consequences of the illness are
constraining and persist during daily life despite
adequate medical therapy.
Besides the two RCTs [7, 8], a limited number of
observational studies have been published in the inter-
national [20–24] and German literature [25–27]. They
have shown positive effects regarding quality of life, clin-
ical symptoms, physical function, exacerbations, and
health care resource utilisation. However, up to now, no
RCTs have addressed the question whether and how
long asthma control improves after PR. Therefore, such
a study was strongly recommended by the German Na-
tional Disease Management Guideline [19].
This lack of evidence is of particular relevance since
asthma is a common indication for PR in Europe and in
the US [6], and is the most frequent indication for PR in
Germany [28]. Therefore, the main objective of the
EPRA-RCT is to fill the knowledge gap for PR in
asthma. Moreover, there is little empirical data regarding
the long-term course of AC, quality of life and self-
management skills after PR for asthma and the cost-
effectiveness. As part of the EPRA study a follow-up
assessments at 6, 9 and 12 months after PR will be
provided.
Study aims
The primary aim of this RCT is to evaluate the effective-
ness of PR for patients with asthma on short (end of
rehabilitation) and intermediate-term (3 months after
rehabilitation) outcomes as compared to a waiting-list
control group. We hypothesize that pulmonary inpatient
rehabilitation is superior regarding mean change in AC
at 3 months after rehabilitation (primary outcome). Fur-
thermore, we expect superior effectiveness of the pul-
monary rehabilitation regarding health related quality of
life (HRQoL), functional exercise capacity, dyspnea, anx-
iety, depression, subjective self-management skills, ill-
ness perceptions, sick leave, as well as subjective work
ability (secondary outcomes). In addition, moderator ef-
fects of (a) gender, (b) age, (c) baseline AC, (d) baseline
HRQoL and (e) baseline anxiety will be examined.
Moreover, in a longitudinal follow-up study, the course
of primary and secondary outcomes over one year and
the annual costs before and after rehabilitation will be
explored.
Methods
Study design and data collection
We use a two part-study design, combining a random-
ized controlled trial (RCT) and a longitudinal follow-up
design.
The main study is a randomized control superiority
trial, comparing the intervention group (IG) with a
waiting-list control group (CG). For legal reasons, any
insurant of the statutory German Pension Insurance
(GPI) whose application for medical rehabilitation was
approved by the GPI will receive a rehabilitative inter-
vention. Therefore, it is not possible to use an entirely
untreated CG, but a waiting-list CG can be realized.
After inpatient rehabilitation in the Bad Reichenhall
Clinic has been approved by the GPI, patients receive a
letter informing about the study and screening for their
eligibility. If no response is received within 14 days, a
reminder will be sent to the patients. If patients meet
the inclusion criteria, they are asked to participate. After
consent has been obtained, participants will be randomized
to the IG or CG. In the IG, participants will start inpatient
rehabilitation within 4 weeks after randomization. Data will
be assessed at randomization (T0), at the beginning (T1),
the end (T2), and three months after inpatient rehabilita-
tion (T3). The CG will start inpatient rehabilitation five
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months (i.e. 20 weeks) after randomization. CG data will be
assessed at randomization (T0), at four weeks (T1), at seven
weeks (T2) and at 20 weeks (T3, beginning of inpatient
rehabilitation) after randomization. The crucial reference
intervals for the primary research questions are T0 to T2
and T0 to T3 for both IG and the CG. Since CG starts PR
19 to 20 weeks after T0, which is 3 months after the dis-
charge time-point of IG, it will be possible to compare the
results of IG with those of the (still) untreated CG during
these initial 19 to 20 weeks. However, it may be possible
that for the CG, arrival at the rehabilitation clinic (at T3)
already has an effect on several outcome parameters. To
estimate this “arrival effect”, an additional measurement
time point (T3a) for the CG at 10 (+/-3) days before T3 has
been included.
The second part of the study is a longitudinal cohort
study. In addition to the data collected in the first part
of the study (RCT), data at 6, 9 and 12 months after
inpatient rehabilitation in the IG and data at the end of
and at 3, 6, 9 and 12 months after inpatient rehabilita-
tion in the CG will be collected. Longitudinal data from
both groups will be combined to one sample. Fig. 1 illus-
trates the study design. Note that measurement time
points of the IG and CG have a parallel timing only from
T0 to T3. Participants not returning the postal question-
naires on time will be reminded by phone. If necessary,
questionnaires will be sent again by mail to the patient.
Patient selection
Patients are eligible for the study if they are approved
for PR, have a physician diagnosis of asthma (ICD-10:
J45) at T0 and have uncontrolled asthma based on an
Asthma Control Test (ACT) <20 [1, 29, 30]. Patients will
be excluded if they have cognitive impairment, inad-
equate German language ability, or severe concomitant
diseases that might mask the results of asthma rehabili-
tation (for example cancer and severe cardiac/orthopedic
or psychiatric comorbidities). The initial diagnosis of
asthma will be confirmed by a pulmonologist at admis-
sion to inpatient rehabilitation. If the initial diagnosis
cannot be confirmed, the patient will be excluded from
the study.
Randomization
Participants will be recruited consecutively. All patients
meeting the inclusion criteria and providing informed
consent are randomly assigned to the IG or CG by a
study nurse at the time of their PR approval.
Randomization will be stratified according to age. The
randomization list (with computer-generated random
numbers) is created by the Department of Medical
Psychology and Psychotherapy, Medical Sociology and
Rehabilitation Sciences at the University of Würzburg
(concealed allocation).
Blinding
Patients themselves cannot be blinded due to the time-
point of the start of their inpatient rehabilitation. How-
ever, those who deliver the rehabilitation treatment are
unaware whether the patient is a study participant, a
participant of the IG or the CG, or a regular inpatient
outside the study.
BPR71260
Fig. 1 Study design and measurement occasions; PR: pulmonary rehabilitation; M: months; W: weeks; not shadowed: data for randomized control
trial; grey shadowed: data used only in the longitudinal study
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Sample size
Calculation of sample size is based on our primary
outcome, the ACT, assessed three months after the
inpatient rehabilitation. A previous longitudinal study of
asthma patients in the Bad Reichenhall Clinic (without a
CG) showed changes between start of inpatient rehabili-
tation and three months after inpatient rehabilitation of
(Cohen’s) d > 0.5 [25]. However, this value might over-
estimate the effect of inpatient rehabilitation compared
to a control group. Therefore, sample size was calculated
to detect a difference of d = 0.3 at T3 between the IG
and CG. Using alpha = 0.05 and power = 0.8, 352 partici-
pants are required, but assuming a drop-out rate of 30%,
a total of n = 504 patients will be recruited [26].
Latent curve models will be used to analyze the course
of the primary outcome in the longitudinal follow-up
study. As a rule of thumb, N > 100 cases should be in-
cluded in the computation of these models. Even with a
conservatively estimated drop-out rate of 50% until T6
for IG and T8 for CG, N = 152 patients would remain in
the study, which is sufficient.
Intervention
As shown in Fig. 1, both groups receive a 3-week PR
that meets the structural requirements of German
healthcare insurance providers [31, 32]. The PR is car-
ried out by a multi-professional team (physicians, psy-
chologists, physiotherapists, sports scientists, social
workers, nutritional consultants) and will be tailored in-
dividually to each patient’s needs. The rehabilitation pro-
gram will be reviewed at least once a week as part of the
doctor’s weekly rehabilitation ward round.
The rehabilitation program includes the following
non-drug therapy components (O = obligatory for all
participants, except those with individual contraindica-
tions, F = facultative if needed):
1. Physical training (O) consisting of three obligatory
components: a) endurance training scheduled for 5
units per week for 45–60 min each, during which
outdoor sports and training in water (e.g. Aqua
Fitness, Nordic Walking) are performed. Exercise
intensity is controlled by BORG Scale and heart rate;
b) strength training scheduled for 3 sessions per
week of 45–60 min each and c) whole-body
vibration-training scheduled 7 times per week. In
addition, inspiratory muscle training (F) is provided
for patients with inspiratory muscle weakness and is
scheduled for 7 sessions per week, each for 21 min,
of which 2 per week are supervised.
2. Comprehensive patient education (O) consisting of
two obligatory components: a.) patient education
regarding asthma for one week with 7 units of 45
min; b.) one session of practical medical inhalation
training and/or peak flow meter use for 60 min. In
addition, patients also receive allergy awareness and
trigger avoidance training (F) if required (one 60-
min session).
3. Respiratory physiotherapy (O) consisting of 3 units
of group respiratory physiotherapy per week with
learning of pursed lips breathing (O) for 45 min
each. If necessary, patients may also receive the
following optional components (F) including: a)
individual breathing training by physiotherapists; b)
training of Buteyko breathing techniques [29] for
patients with dysfunctional breathing [30]; c)
physiotherapy seminar on coughing techniques for
patients with cough problems; d) mucolytic
inhalation therapies (e.g. saline inhalation, for
patients with mucostasis (4).
4. Psychosocial support (F) such as social counseling,
individual psychological counseling and/or group
therapy will be offered if necessary (Patient Health
Questionnaire (PHQ-9) > 9 points, Generalized
Anxiety Questionnaire (GAD-7) > 9 points or if
indicated by their physicians).
5. Comprehensive smoking cessation program (F) will
be offered to all smokers.
6. Comprehensive nutritional counseling (F) will be
offered to patients with food intolerance or allergies
or over- and underweight.
In addition, patients will receive a routine check-up
and if necessary, current asthma medications will be
optimized according to the current guidelines. This is
an obligatory part of the rehabilitation in Germany.
Any changes to medications will be documented.
Adverse events and complications during rehabilita-
tion are recorded by the physicians on a standardized
basis in the medical survey sheet at the end of
rehabilitation.
Outcomes and measures
The primary outcome is the mean change in AC,
assessed by ACT. Secondary outcomes include mean
changes in HRQoL, 6-min walk distance (6-MWD) and
Sit-to-stand-test, lung function parameters, Eosinophils,
dyspnea, depression, anxiety, smoking habits, illness rep-
resentations, self-management skills, work ability, sub-
jective prognosis of return to work, sick leave,
medication beliefs and medication adherence. Measure-
ment instruments for all outcomes and measurement
occasions can be found in Table 1. Lung function
parameters, 6-MWD, FeNO, and Eosinophils are
assessed at the start and the end of the inpatient re-
habilitation by staff of the PR. All other outcomes are
assessed via questionnaires.
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Assessment of outcomes
Asthma control
Asthma Control will be assessed by using the Asthma
Control Test (ACT) [30, 33]. The ACT consists of five
items that assess (1) activity limitation, (2) daytime
shortness of breath, (3) awaking due to asthma symp-
toms, (4) needed puffs of reliever medication and (5) a
global judgment of asthma control. All items refer to the
last 4 weeks. They are scaled from 1 to 5. The sum of
scores indicates asthma control. An ACT score of 20 –
25 indicates controlled asthma and of <20 indicates
uncontrolled asthma. A minimal important difference
about 3 was identified [34].
Health related quality of life
Asthma specific HRQoL will be assessed by both, the
Saint George’s Respiratory Questionnaire (SGRQ) [35]
and the standardized version of the Asthma Quality of
Life Questionnaire (AQLQ) [36]. The SGRQ uses 50
items to capture the three domains Symptoms, Activity
and Impacts as well as a Total scale. All scales are com-
puted by weighted sums of the respective items. The
scores range from 0 (no impairment) to 100 (maximum
impairment). A minimal important difference (MID) of
4 is established for COPD, a MID for asthma has not
been reported up to now. The standardized version
Asthma Quality of Life Questionnaire (AQLQ) contains
32 questions to capture the four domains Symptoms, Ac-
tivity limitation, Emotional function and Environmental
stimuli to measure the functional problems that are
most troublesome to adults with asthma. The survey
period covers the past 2 weeks. Each question is
answered on a 7-point scale (1 = severely impaired - 7 =
not impaired at all). The overall AQLQ score is the
mean of all 32 responses and the individual domain
scores are the means of the items from those domains.
Table 1 outcome measures
Outcome measured by/Instrument T0 T1 T2 T3A (CG) T3 T4 T5 T6 T7 (CG) T8 (CG)
Asthma control Asthma control test (ACT) [29, 30] X X X X X X X X X X
Lung function,
blood gases
FEV1, FEV1/VC, SRtot, VC, RV, PaO2, PaCO2, [50, 51] IG IG CG CG
Exercise capacity 6MWT [53]
Allergy Total Ig E, specific Ig E-Screening (ImmunoCAP®) IG IG CG CG
Asthmatic inflammation Fractional exhaled nitric oxide (FeNO) [56], Eosinophils IG IG CG CG
QoL Saint George’s Respiratory Questionnaire (SGRQ) [35] X X X X X X X X X X
QoL Asthma Quality of Life Questionnaire (AQLQ)] [36] X X X X X X X X X X
QoL EQ-5D-5L [37, 38, 57] X X X X X X X X X X
QoL Global Rating of Change Scale (GROC-scale) [39] X X X X X X X X
Symptoms Numerical rating scale for dyspnoea, cough,
sputum, pain [40]
X X X X X X X X X
Dysfunctional breathing Nijmegen Questionnaire (NQ) [58] X X X X X X
Depression Patient Health Questionnaire (PHQ) [59] X X X X X X X X X
Anxiety Generalized Anxiety Disorder Questionnaire
(GAD 7) [60]
X X X X X X X X X
Fatigue Brief Fatigue Inventory (BFI) [41] X X X X
Illness Perception Illness Perception Questionnaire (IPQ-R)
German Version [45]
X X X X X X X X X
Resource Use FIM-Lu, modification of FIMA [52] X X X X X X X
Work ability Work Ability Index (WAI) Items 1 and 4 [61] X X X X X X X X X
SPoRTW SPE-Scale [55] X X X X X X X X X
Self-management Health Education Impact Questionnaire (heiQ),
Scale “Skill and technique acquisition”
X X X X X X X X X
Smoking habits Questionnaire (developed) X X X X X X X
Sport behaviour Questionnaire (developed) X X X X X X X
Medication beliefs Brief Medication Questionnaire (BMQ) [62] X X X X X X X
Adherence Medication Adherence Report Scale (MARS) [63] X X X X X X X
Sick leave Questionnaire (developed) IG X X X X X
Notes: QoL: Quality of Life; SPoRT: Subjective prognosis of return to work; IG: assessment only in intervention group; CG: assessment only in control grou
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Generic HRQoL of patients is measured using the
Euroqol questionnaire (EQ-5D-5L) and the EQ visual
analogue scale (VAS). The EQ-5D-5L [37] is a standard-
ized instrument applicable to a wide range of health
conditions for use as a measure of health outcome. It is
especially suited to cost effectiveness analyses as it can
be used to generate quality-adjusted life years [38]. The
descriptive system of the EQ-5D-5L comprises five
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, anxiety/depression). Each dimension has five
levels: no problems, slight problems, moderate prob-
lems, severe problems, and extreme problems. A
German utility index is currently being developed.
Subjective health
Global rating of change (GRC) [39] in subjective health
is assessed using a single item that compares current
subjective health with subjective health at the beginning
of the inpatient rehabilitation. The response scale ranges
from -7 (much worse) over 0 (no change) to 7 (much
better).
Symptoms
Severity of dyspnea, cough, sputum and pain will be
assessed with response to seven 11-point numeric rating
scales [40]. Scale values range from 0 (no symptoms) to
10 (worst imaginable symptom severity).
Fatigue
The Brief Fatigue Inventory (BFI) will be used to meas-
ure fatigue. This short questionnaire assesses severity of
and impairment from fatigue with ten questions. The
subscales and the total score range from 0 to 10, with
higher values indicating higher severity/impairment. A
German version exists and has been proven reliable and
valid [41].
Depression and anxiety
The PHQ-9 and the GAD-7 will be used to assess
depression [42] and anxiety [43, 44]. All items are scored
on a 4-point Likert scale (0 = not at all, 1 = several days;
2 =more than half of the days; 3 = nearly all days).
Besides using the sum of scores (which range from 0 to
27 in PHQ and 0 to 21 in GAD-7), we will also classify
individuals with values of >10 as indicating a clinically
relevant depressive disorder (PHQ-9) or a clinically rele-
vant anxiety disorder (GAD-7).
Illness representation
The 9-item Brief-Illness Perception Questionnaire (B-
IPQ) [45] will be used to capture 8 aspects of illness rep-
resentations (i.e how illness perceived by the patient:
Consequences, Timeline, Personal control, Treatment
control, Identity, Concern, Understanding and Emotional
response. Each aspect is assessed by one item, except for
Emotional response, which is assessed by two items. All
items use a 0 to 10 response scale. Furthermore,
perceived causes of asthma attacks are assessed via an
open-ended response item, which asks for the three
most important causal factors of their illness.
Subjective self-management
Subjective self-management will be assessed using the
Skill and technique acquisition scale from the Health
Education Impact Questionnaire (heiQTM, [46, 47]). The
items are scored on a 4-point response scale (1 =
strongly disagree, 2 = disagree, 3 = agree, 4 = strongly
agree). The overall score is computed as the unweighted
mean of all items, with higher values indicating a higher
subjective judgement of self-management.
Medication adherence and medication beliefs
Patients will complete the Medication Adherence Report
Scale (MARS-D) [48]. This is a 5-item questionnaire
with a 5-point response scale (1 = always to 5 = never).
The sum of the individual answers can range from 5 to
25 points, with higher values indicating better medica-
tion adherence. The 10-item Brief Medication Question-
naire (BMQ) [49] will be used to assess patient’s
medications beliefs on two scales. The scale Necessity as-
sesses patients’ beliefs about the necessity of prescribed
instruments and the scale Concern assesses patients’
concerns about prescribed medications. Both scales
range from 5 to 25 points with higher values indicating
higher belief of necessity/higher concerns.
Lung function measurement
Forced expiration in one second (FEV1), vital capacity
(VC), residual volume (RV) and total specific resistance
(SRtot) are determined using spirometry and body plethys-
mography (MasterLab, CareFusion, Hoechberg, Germany)
before and after bronchodilation with a short-acting bron-
chodilator in accordance with recommendations of the
national guidelines [50, 51].
Resource use
Resource use will be determined based on answers to
the FIMA-Lu questionnaire, a modified Version of the
FIMA questionnaire, a German instrument to assess
health-related resource use [52]. For direct costs, the
number of visits to a general practitioner, specialist care,
ambulatory clinics in hospital, physiotherapy, days spent
in hospitals and intensive care units and medication
administered will be documented. For indirect costs,
work absenteeism days will be documented.
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Exercise Capacity
The 6-MWD will be measured using a track length of 30
m according to the European Respiratory Society/Ameri-
can Thoracic Society technical standards [53]. At T0 and
T1 respectively, each patient performs the test twice
with an interval of one hour. The best test will be
included for analysis.
Work ability
Subjective work ability will be assessed by the first item
of the Work Ability Index (WAI), the Work Ability Score
(WAS). It compares current subjective work ability to
the lifetime’s best. The 11-point scale ranges from 0
(complete incapacity to work) to 10 (lifetime’s best work
ability). The WAS shows high correlations with the over-
all WAI score [54]. Furthermore, the 4th Item of the
WAI is used to assess health-related limitation of
current work ability, with values ranging from 1 (total
incapacity to work) to 6 (no limitation). In addition, sub-
jective prognosis of employment status will be assessed
using the 3- items of the Subjective Prognostic Employ-
ment Scale (SPE Scale). The three items assess patient’s
belief (a) to remain at work until retirement and (b)
whether their health will be permanently jeopardized
and (c) whether they are considering applying for a
disability pension [55].
Sport activity, smoking habits and medication use
Two items will be used to assess sport activity. In Item
1, the patient indicates whether he or she exercises regu-
larly (at least 2 times per week) and in item two the kind
of exercise performed (e.g. gym, sports club, lung sport
group). Current smoking status (current smoking yes or
no) and number of cigarettes per day will be docu-
mented. Furthermore, patients’ use of antibiotics or cor-
tisone in the last three months (yes/no; number of uses)
will be documented.
Socio-demographic data and employment
Information regarding socio-demographic data and
employment status will be collected.
Data management Data of all measurement time-
points will be collected in the Bad Reichenhall Clinic.
Questionnaire data will be entered into Microsoft Excel
by two study nurses (independent double data entry by
two individuals). A unique ID number will be assigned
to each patient and personal data (name, address) will be
stored in a completely separate file. The list with
assigned ID numbers and personal data will be stored in
the Bad Reichenhall Clinic and will not leave the center.
Other anonymized data will be sent to the University of
Wuerzburg and the Helmholtz Zentrum Munich for fur-
ther data management and data analyses.
Statistical methods
Primary and secondary outcomes will be analyzed
according to the intention to treat approach [56]. All
randomized patients will be included in the analysis.
Missing data fulfilling the assumption of missing (com-
pletely) at random will be imputed using multiple imput-
ation procedures [57]. In addition, because it may be
possible that some patients will not start with the
inpatient rehabilitation or decide to drop-out of the
study, we will also analyze results based on a “per proto-
col” approach [58, 59] including only patients remaining
in the study until T3.
The analysis of the primary and secondary outcomes
at T2/T3 will use analysis of covariance (ANCOVA) with
treatment group as a fixed effect and baseline value of
the respective outcome as a covariable. Adjusted mean
differences and confidence intervals will be reported. In
addition, moderating effects [60] of the following base-
line variables on the primary outcome will be analyzed:
ACT, gender, age, quality of life (assessed via SGRQ
Total Score), anxiety (assessed using GAD-7) and
depression (assessed using PHQ-7). For all models, stat-
istical model assumptions (linearity, homoscedasticity,
normality of residuals) will be tested. If model assump-
tions are violated, appropriate analysis methods (e.g. ro-
bust regression, log-transformation) will be used.
Latent change models will be used for exploratory ana-
lyses of the course of the primary and the secondary out-
comes in the follow-up longitudinal study [61, 62].
Economic evaluation
Data regarding resource utilization and work absentee-
ism will be documented retrospectively by the patient. A
self-administrated questionnaire based on the FIMA
questionnaire [52] has been developed specifically for
patients with pulmonary problems. The monetary valu-
ation of resource use will be based on the valuation rates
calculated by Bock et al. [63]. Analysis of cost data will
be performed with a model with a gamma distribution
and a log-link to account for the skewed distribution of
the data [64]. A 95% confidence interval for the cost dif-
ference will be estimated based on 1,000 bootstrap repli-
cations using the percentile method.
In the longitudinal follow-up study, the annual costs
before and after rehabilitation will be compared by
paired t-test. Alternatively, bootstrap resampling with
1,000 resamples will be used to compute p-values be-
cause cost differences may have a skewed distribution.
All statistical Analysis will be performed using SPSS
[65], R [66] & SAS software [67].
Discussion
Asthma is one of the most common chronic diseases
worldwide with an estimated 300 million affected
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individuals [1]. Although effective medications are avail-
able, asthma remains incurable and poorly controlled for
numerous patients in many countries [3, 4]. In Europe
and in North America, asthma patients are commonly
enrolled in PR programs [6] but the data available
regarding PR of patients with asthma are sparse. This
will be the first RCT to assess the effectiveness of a com-
plex inpatient pulmonary rehabilitation regarding
asthma control. The intervention conforms to the qual-
ity guidelines of the German Statutory Pension Insur-
ance and follows national and international guidelines
for pulmonary rehabilitation. Therefore, the results of
this study may be generalizable. Furthermore, relevant
medical and economic information will be generated for
third-party payers, on which they can base their deci-
sions regarding long-term management of asthma.
The findings of this study will be published in peer-
reviewed journals and conference presentations.
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(Immunoglobulin E) antibody blood levels; HRQoL: Health related quality of
life; MARS-D: Medication Adherence Report Scale; MID: Minimal important
difference; PaCO2: partial pressure of arterial carbon dioxide; PaO2: partial
pressure of arterial oxygen; PHQ: Patient Health Questionnaire; PR: Pulmonary
Rehabilitation; QoL: Quality of Life; RCT: Randomized controlled trial;
RV: Residual Volume; SGRQ: St. George Respiratory Questionnaire; SPE
Scale: Subjective Prognostic Employment Scale; SPoRT: Subjektive prognosis
of return to work; SRtot: Total specific resistance; Total Ig E: total
Immunoglobulin E; VC: Vital capacity; WAI: Work Ability Index; WAS: Work
Ability Score
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